**
The plight of individuals suffering from hypermobile Ehlers-Danlos syndrome (hEDS) has come to the forefront, revealing a shocking reality where patients endure agonising waits—often stretching up to 21 years—for a diagnosis. This alarming trend not only affects their health and wellbeing but also highlights the systemic failures within the UK healthcare system. As awareness grows, so too does the urgency for better understanding and treatment of this debilitating condition.
The Reality of Life with hEDS
One poignant account comes from a 34-year-old former drama student who has seen her life unravel due to hEDS. She recalls that her struggles began at the tender age of 19, leading to surgeries and a cancer diagnosis just five years later. Now, chronic pain and fatigue dominate her existence. “For eight years, my nervous system has been so unstable that I have been unable to read, watch TV or tolerate light,” she shares. At her worst, basic communication became a challenge, leaving her unable to spell simple words or form coherent sentences.
The journey towards understanding her condition has been fraught with obstacles. The patient, who wishes to remain anonymous, sought answers through private healthcare in England rather than the NHS in Scotland. The financial burden placed on her family has been immense, raising a critical question: What happens to those without such support?
A Systemic Oversight
Despite the increasing recognition of hEDS, many patients undergo psychiatric misdiagnoses before receiving the correct diagnosis, with studies indicating that 94.4% of individuals experience this frustrating detour. Additionally, many are never tested for related conditions such as postural orthostatic tachycardia syndrome (POTS) or mast cell activation syndrome (MCAS), despite the clear symptom overlap.
The statistics are sobering; with hEDS affecting approximately one in 227 people in the UK, a staggering 95% of those remain undiagnosed. Research underscores the severity of the condition, showing that the disability burden linked to hEDS is comparable to that of multiple sclerosis. Yet, funding for research remains disproportionately low.
Gender Disparities and the Need for Change
A distressing trend emerges when examining the demographics of hEDS sufferers: 90% are women, and they face diagnostic delays averaging 15 years. This lengthy journey to diagnosis is compounded by a high suicide-attempt rate of 17.8% among patients, highlighting the urgent need for a comprehensive review of resources and funding dedicated to hEDS.
One mother shared her experience of navigating the healthcare system to secure a diagnosis for her daughter, which took 15 years of relentless effort. Despite finally receiving the diagnosis, there has been little progress in terms of treatment, leaving her daughter to manage her condition through exercise and diet while living with constant pain. “A diagnosis is very helpful, but not when it isn’t accompanied by a treatment plan,” she notes poignantly.
The Call for Action
The overwhelming consensus among patients and advocates is clear: immediate action is required. There is a pressing need for formal reviews and increased investment in research dedicated to hEDS. Without this, countless lives remain at risk, and the hidden crisis of undiagnosed hypermobility will continue to escalate.
Why it Matters
The struggles of those with hypermobile Ehlers-Danlos syndrome reflect a broader issue within the healthcare system, where lack of awareness and understanding can lead to devastating consequences. The call for better diagnosis, treatment options, and research funding is not merely a request for assistance; it is a plea for dignity and hope. As we confront this public health catastrophe, the lives of thousands hang in the balance. It is imperative that we listen, learn, and advocate for change, ensuring that no one has to endure the torturous wait for recognition and care that so many have faced.
